亚砷酸注射液对原发性肝癌不同证型预后的影响

Effect of arsenictrioxide on prognosis of patients with primary hepatic carcinoma with different syndrome

关键词:  亚砷酸  肝癌  中医证型

Key words:  arsenictrioxide  primary hHepatic carcinoma  types of syndrome

摘要:

[目的]探讨亚砷酸注射液对原发性肝癌不同中医证型预后的影响。[方法]将75例中晚期原发性肝癌患者随机分为两组,治疗组45例,对照组30例。对照组仅接受单纯中药辨证治疗和一般对症、支持治疗,治疗组在对照组治疗基础上还接受亚砷酸注射液治疗。[结果]1)治疗组比对照组中位生存时间明显延长(219 d:182 d),但在3种中医证型中,仅肝盛脾虚型患者与对照组比较有差异。2)接受亚砷酸治疗后患者的生存危险下降,为对照组的0.371倍(P<0.01),肝热血瘀型及肝肾阴虚型患者的死亡风险分别是肝盛脾虚型患者的3.35和11.85倍。[结论]亚砷酸注射液能够明显改善中晚期肝癌患者的预后,降低其死亡风险。其中以对肝盛脾虚型效果最好。

Abstract:

[Objective] To explore the effect of Arsenictrioxide on the prognosis of patients with primary hepatic carcinoma in different syndrome.[Methods] Seventy-five patients with middle or advanced primary liver cancer were randomly divided into two groups(treat-ment group with 45 patients and control group with 30 patients).The patients of control group were treated Chinese traditional medicine only by differentiation of symptoms and signs and routine symptom and supported therapy.The patients of treatment group were treated by Arsenictrioxide and Chinese traditional medicine.[Results] The median survive time in the treatment group was significantly longer than that of the control group(219 d Vs 182 d).Comparing with the control group,only the patients with syndrome of Ganshengpixu was statis-tically different.After receiving treatment of Arsenictrioxide,the survival risk of treatment group decreased,being 0.371 fold of the con-trol group(P<0.01).The survival risk of patients with syndrome of Ganrexueyu or the syndrome of Ganshenyinxu were respectively 3.35 times and 11.85 times than that of the patients with syndrome of Ganshengpixu.[Conclusions] For the patients with middle or advanced primary hepatic carcinoma,Arsenictrioxide injection can improve the prognosis and lower the survival risk.The effect of the patients with syndrome of Ganshengpixu was the best.